FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:688-699 September 4, 1997 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In addition, danaparoid sodium, which is a mixture of dermatan sulfate, heparan sulfate, and chondroitin sulfate, is often used for the treatment of heparin-induced thrombocytopenia.¹ Low-molecular-weight heparins have replaced unfractionated heparin in many parts of Europe but are only now finding their place in North America. Their use is . . . [Full Text of this Article]

Mechanisms of Action of Low-Molecular-Weight Heparins

Pharmacokinetics of Low-Molecular-Weight Heparins

Clinical Studies

Prophylaxis against Thromboembolism

General Surgery

Orthopedic Surgery of the Lower Limb

            Total Hip Replacement

            Total Knee Replacement

            Surgery for Hip Fracture

Acute Spinal Cord Injury

Multiple Trauma

Medical Conditions

Patency of Femoropopliteal Bypass Grafts

Restenosis after Angioplasty

Treatment of Thrombosis

Venous Thrombosis

Unstable Angina

Ischemic Stroke

Remaining Questions

Preoperative or Postoperative Dosing with Low-Molecular-Weight Heparins

Once-Daily versus Twice-Daily Dosing

Risk of Heparin-Induced Thrombocytopenia

Neutralization of Low-Molecular-Weight Heparins with Protamine Sulfate

Safety of Low-Molecular-Weight Heparins in Pregnancy

Risk of Heparin-Induced Osteoporosis

Comparability of Various Preparations of Low-Molecular-Weight Heparin

Cost Effectiveness

Summary

Source Information

From the Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ont., Canada.

Address reprint requests to Dr. Weitz at the Hamilton Civic Hospitals Research Centre, 711 Concession St., Hamilton, ON L8V 1C3, Canada.

References

Related Letters:

Low-Molecular-Weight Heparins
Horlocker T. T., Weitz J. I.
Extract | Full Text  
N Engl J Med 1998; 338:687-688, Mar 5, 1998. Correspondence

Enoxaparin in Neurosurgical Patients
Connolly E. S., Mocco J, Agnelli G., Iorio A.
Extract | Full Text  
N Engl J Med 1998; 339:1639-1640, Nov 26, 1998. Correspondence

This article has been cited by other articles:

• Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., Weitz, J. I. (2008). Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 141S-159S [Abstract] [Full Text]  
• Goodman, S. G., Menon, V., Cannon, C. P., Steg, G., Ohman, E. M., Harrington, R. A. (2008). Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 708S-775S [Abstract] [Full Text]  
• Bates, S. M., Greer, I. A., Pabinger, I., Sofaer, S., Hirsh, J. (2008). Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 844S-886S [Abstract] [Full Text]  
• Gross, P. L., Weitz, J. I. (2008). New Anticoagulants for Treatment of Venous Thromboembolism. Arterioscler. Thromb. Vasc. Bio. 28: 380-386 [Abstract] [Full Text]  
• Rivas-Gandara, N, Ferreira-Gonzalez, I, Tornos, P, Torrents, A, Permanyer-Miralda, G, Nicolau, I, Arellano-Rodrigo, E, Vallejo, N, Igual, A, Soler-Soler, J (2008). Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart 94: 205-210 [Abstract] [Full Text]  
• Levy, J. H., Tanaka, K. A., Bailey, J. M. (2008). Cardiac Surgical Pharmacology. Card Surg Adult 3: 77-110 [Full Text]  
• Merry, A. F. (2007). Focus on Thrombin: Alternative Anticoagulants. SEMIN CARDIOTHORAC VASC ANESTH 11: 256-260 [Abstract]  
• Al-Ansari, E., Du, H.-k., Yu, L., Ochoa, C. D., Garg, H. G., Quinn, D. A., Hales, C. A. (2007). Low-Molecular-Weight Heparin Inhibits Hypoxic Pulmonary Hypertension and Vascular Remodeling in Guinea Pigs. Chest 132: 1898-1905 [Abstract] [Full Text]  
• Murphy, S. A., Gibson, C. M., Morrow, D. A., Van de Werf, F., Menown, I. B., Goodman, S. G., Mahaffey, K. W., Cohen, M., McCabe, C. H., Antman, E. M., Braunwald, E. (2007). Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28: 2077-2086 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Gibson, C. M., Murphy, S. A., Montalescot, G., Morrow, D. A., Ardissino, D., Cohen, M., Gulba, D. C., Kracoff, O. H., Lewis, B. S., Roguin, N., Antman, E. M., Braunwald, E., for the ExTRACT-TIMI 25 Investigators, (2007). Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial. J Am Coll Cardiol 49: 2238-2246 [Abstract] [Full Text]  
• De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J. (2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J 0: ehl492v1-34 [Full Text]  
• Stine, K. C., Saylors, R. L., Suzanne Saccente, C., Becton, D. L. (2007). Treatment of Deep Vein Thrombosis With Enoxaparin in Pediatric Cancer Patients Receiving Chemotherapy. CLIN APPL THROMB HEMOST 13: 161-165 [Abstract]  
• Bar-Yosef, S., Cozart, H. B., Phillips-Bute, B., Mathew, J. P., Grocott, H. P. (2007). Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery: [L'heparine de bas poids moleculaire en preoperatoire reduit la reponse a l'heparine pendant la chirurgie cardiaque]. Canadian J. Anesthesia 54: 107-113 [Abstract] [Full Text]  
• Sabatini, L., Torricelli, M., Scaccia, V., Fineschi, D., Pescaglini, M., Gasparri, L., Florio, P., Petraglia, F. (2007). Increased Plasma Concentrations of Antiprothrombin Antibodies in Women with Recurrent Spontaneous Abortions. Clin. Chem. 53: 228-232 [Abstract] [Full Text]  
• Collet, J.-P., Dumaine, R., Montalescot, G. (2007). Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. Eur Heart J Suppl 9: A11-A24 [Abstract] [Full Text]  
• Bates, S. M. (2007). Management of Pregnant Women with Thrombophilia or a History of Venous Thromboembolism. ASH Education Book 2007: 143-150 [Abstract] [Full Text]  
• Bittl, J. A. (2006). Accounting for ACUITY.. NEJM 355: 2249-2250 [Full Text]  
• Lee, Y. H., Lee, J. Y., Kim, Y. S., Kim, D. H., Kim, J. (2006). Successful Anticoagulation for Bilateral Central Retinal Vein Occlusions Accompanied by Cerebral Venous Thrombosis. Arch Neurol 63: 1648-1651 [Abstract] [Full Text]  
• Deitcher, S. R., Kessler, C. M., Merli, G., Rigas, J. R., Lyons, R. M., Fareed, J. (2006). Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.. CLIN APPL THROMB HEMOST 12: 389-396 [Abstract]  
• Milovic, N. M., Behr, J. R., Godin, M., Hou, C.-S. J., Payer, K. R., Chandrasekaran, A., Russo, P. R., Sasisekharan, R., Manalis, S. R. (2006). Monitoring of heparin and its low-molecular-weight analogs by silicon field effect. Proc. Natl. Acad. Sci. USA 103: 13374-13379 [Abstract] [Full Text]  
• Carson, J. L. (2006). Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost.. JAMA 296: 991-993 [Full Text]  
• Motte, S., Samama, C. M., Guay, J., Barre, J., Borg, J.-Y., Rosencher, N. (2006). Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis: [La prevention de la thromboembolie veineuse postoperatoire. Evaluation du risque et methodes de prophylaxie]. Canadian J. Anesthesia 53: S68-S79 [Abstract] [Full Text]  
• Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., Lopez-Sendon, J. L., Guneri, S., Jiang, F., White, H. D., Fox, K. A.A., Braunwald, E., the ExTRACT-TIMI 25 Investigators, (2006). Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. NEJM 354: 1477-1488 [Abstract] [Full Text]  
• Ellis, M. H., Hadari, R., Tchuvrero, N., Shapira, S., Kovlenko, I., Kozmiakova, M., Zissin, R., Elis, A. (2006). Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice. CLIN APPL THROMB HEMOST 12: 199-204 [Abstract]  
• Kulik, A., Rubens, F. D., Wells, P. S., Kearon, C., Mesana, T. G., van Berkom, J., Lam, B.-K. (2006). Early Postoperative Anticoagulation After Mechanical Valve Replacement: A Systematic Review. Ann. Thorac. Surg. 81: 770-781 [Abstract] [Full Text]  
• Meurin, P., Tabet, J. Y., Weber, H., Renaud, N., Driss, A. B. (2006). Low-Molecular-Weight Heparin as a Bridging Anticoagulant Early After Mechanical Heart Valve Replacement. Circulation 113: 564-569 [Abstract] [Full Text]  
• Elkayam, U., Bitar, F. (2005). Valvular Heart Disease and Pregnancy: Part II: Prosthetic Valves. J Am Coll Cardiol 46: 403-410 [Abstract] [Full Text]  
• Jones, H. U., Muhlestein, J. B., Jones, K. W., Renlund, D. G., Bair, T. L., Bunch, T. J., Horne, B. D., Lappe, D. L., Anderson, J. L., Doty, D. B. (2005). Early Postoperative Use of Unfractionated Heparin or Enoxaparin is Associated with Increased Surgical Re-Exploration for Bleeding. Ann. Thorac. Surg. 80: 518-522 [Abstract] [Full Text]  
• Smith, R. G. (2005). Low-Molecular-Weight Heparins: An Overview for the Podiatric Physician. J. Am. Podiatr. Med. Assoc. 95: 383-389 [Abstract] [Full Text]  
• Klerk, C. P.W., Smorenburg, S. M., Otten, H.-M., Lensing, A. W.A., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M.E.M., Richel, D. J., van Tienhoven, G., Buller, H. R. (2005). The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy. JCO 23: 2130-2135 [Abstract] [Full Text]  
• Zed, P. J., Filiatrault, L., Busser, J. R. (2005). Outpatient treatment of venous thromboembolic disease based in an emergency department. Am J Health Syst Pharm 62: 616-619 [Abstract] [Full Text]  
• Olivero, A. G., Eigenbrot, C., Goldsmith, R., Robarge, K., Artis, D. R., Flygare, J., Rawson, T., Sutherlin, D. P., Kadkhodayan, S., Beresini, M., Elliott, L. O., DeGuzman, G. G., Banner, D. W., Ultsch, M., Marzec, U., Hanson, S. R., Refino, C., Bunting, S., Kirchhofer, D. (2005). A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo. J. Biol. Chem. 280: 9160-9169 [Abstract] [Full Text]  
• Kalus, J. S, Moser, L. R (2005). Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction. The Annals of Pharmacotherapy 39: 481-491 [Abstract] [Full Text]  
• Presta, M., Oreste, P., Zoppetti, G., Belleri, M., Tanghetti, E., Leali, D., Urbinati, C., Bugatti, A., Ronca, R., Nicoli, S., Moroni, E., Stabile, H., Camozzi, M., Hernandez, G. A., Mitola, S., Dell'Era, P., Rusnati, M., Ribatti, D. (2005). Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight-Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists. Arterioscler. Thromb. Vasc. Bio. 25: 71-76 [Abstract] [Full Text]  
• Buzun, L., Kleszczewski, T., Kostrzewska, A., Lisowski, P., Oleksza, P., Jackowski, R., Pedzinska, A., Hirnle, T. (2004). Influence of low molecular weight heparin preparations on human internal thoracic artery contraction. Eur. J. Cardiothorac. Surg. 26: 951-955 [Abstract] [Full Text]  
• McGuire, M., Dobesh, P. P. (2004). Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism. Journal of Pharmacy Practice 17: 289-307 [Abstract]  
• Das, P., Moliterno, D. J. (2004). Fractionating Heparin--Reply. JAMA 292: 1427-1428 [Full Text]  
• Young, G., Yonekawa, K. E, Nakagawa, P., Nugent, D. J (2004). Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion 19: 283-288 [Abstract]  
• Pereira, J., Phan, T. (2004). Management of Bleeding in Patients with Advanced Cancer. The Oncologist 9: 561-570 [Abstract] [Full Text]  
• Hirsh, J., Raschke, R. (2004). Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S-203S [Abstract] [Full Text]  
• Bates, S. M., Greer, I. A., Hirsh, J., Ginsberg, J. S. (2004). Use of Antithrombotic Agents During Pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 627S-644S [Abstract] [Full Text]  
• McRae, S. J., Ginsberg, J. S. (2004). Initial Treatment of Venous Thromboembolism. Circulation 110: I-3-I-9 [Abstract] [Full Text]  
• Weitz, J. I. (2004). New Anticoagulants for Treatment of Venous Thromboembolism. Circulation 110: I-19-I-26 [Abstract] [Full Text]  
• Macie, C., Forbes, L., Foster, G. A., Douketis, J. D. (2004). Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome. Chest 125: 1616-1621 [Abstract] [Full Text]  
• Elkayam, U., Singh, H., Irani, A., Akhter, M. W. (2004). Anticoagulation in Pregnant Women With Prosthetic Heart Valves. J CARDIOVASC PHARMACOL THER 9: 107-115 [Abstract]  
• Thorevska, N., Amoateng-Adjepong, Y., Sabahi, R., Schiopescu, I., Salloum, A., Muralidharan, V., Manthous, C. A. (2004). Anticoagulation in Hospitalized Patients With Renal Insufficiency: A Comparison of Bleeding Rates With Unfractionated Heparin vs Enoxaparin. Chest 125: 856-863 [Abstract] [Full Text]  
• Quinlan, D. J., McQuillan, A., Eikelboom, J. W. (2004). Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials. ANN INTERN MED 140: 175-183 [Abstract] [Full Text]  
• Rich, M. W. (2004). The Management of Venous Thromboembolic Disease in Older Adults. J. Gerontol. A Biol. Sci. Med. Sci. 59: M34-41 [Abstract] [Full Text]  
• Medalion, B., Frenkel, G., Patachenko, P., Hauptman, E., Sasson, L., Schachner, A. (2003). Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 126: 1875-1879 [Abstract] [Full Text]  
• Nutescu, E. A, Shapiro, N. L, Feinstein, H., Rivers, C. W (2003). Tinzaparin: Considerations for Use in Clinical Practice. The Annals of Pharmacotherapy 37: 1831-1840 [Abstract] [Full Text]  
• Fanikos, J., Tsilimingras, K. (2003). Comment: venous thromboembolism prophylaxis conversion in nonsurgical inpatients. The Annals of Pharmacotherapy 37: 1914-1915 [Full Text]  
• Di Cera, E. (2003). Atherosclerosis: Testing the Water. Arterioscler. Thromb. Vasc. Bio. 23: 1713-1714 [Full Text]  
• Wiebe, E. M., Stafford, A. R., Fredenburgh, J. C., Weitz, J. I. (2003). Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide. J. Biol. Chem. 278: 35767-35774 [Abstract] [Full Text]  
• Ross, I. B., Dhillon, G. S. (2003). Ventriculostomy-related Cerebral Hemorrhages after Endovascular Aneurysm Treatment. Am. J. Neuroradiol. 24: 1528-1531 [Abstract] [Full Text]  
• Lee, A. Y.Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., Gent, M., the Randomized Comparison of Low-Molecular-Weight, (2003). Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. NEJM 349: 146-153 [Abstract] [Full Text]  
• Bott, J. N., Reddy, K., Krick, S. (2003). Bivalrudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg. 76: 273-275 [Abstract] [Full Text]  
• Tovey, C., Wyatt, S. (2003). Diagnosis, investigation, and management of deep vein thrombosis. BMJ 326: 1180-1184 [Full Text]  
• Caine, G. J., Lip, G. Y. H. (2003). Is Low-Molecular-Weight Heparin Safer Than Warfarin for Secondary Prevention of Venous Thromboembolism in Cancer Patients?. Arch Intern Med 163: 1243-1244 [Full Text]  
• Payne, S. M, Kovacs, M. J (2003). Cutaneous Dalteparin Reactions Associated with Antibodies of Heparin-Induced Thrombocytopenia. The Annals of Pharmacotherapy 37: 655-658 [Abstract] [Full Text]  
• Ginsberg, J. S., Chan, W. S., Bates, S. M., Kaatz, S. (2003). Anticoagulation of Pregnant Women With Mechanical Heart Valves. Arch Intern Med 163: 694-698 [Abstract] [Full Text]  
• Hylek, E. M., Regan, S., Henault, L. E., Gardner, M., Chan, A. T., Singer, D. E., Barry, M. J. (2003). Challenges to the Effective Use of Unfractionated Heparin in the Hospitalized Management of Acute Thrombosis. Arch Intern Med 163: 621-627 [Abstract] [Full Text]  
• Cohen, M. (2003). The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol 41: 55S-61S [Abstract] [Full Text]  
• Marmur, J. D., Anand, S. X., Bagga, R. S., Fareed, J., Pan, C.-M., Sharma, S. K., Richard, M. F. (2003). The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 41: 394-402 [Abstract] [Full Text]  
• Caughey, G. H. (2003). Building A Better Heparin. Am. J. Respir. Cell Mol. Bio. 28: 129-132 [Full Text]  
• Wong, G. C., Giugliano, R. P., Antman, E. M. (2003). Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention. JAMA 289: 331-342 [Abstract] [Full Text]  
• Bhatt, D. L., Lee, B. I., Casterella, P. J., Pulsipher, M., Rogers, M., Cohen, M., Corrigan, V. E., Ryan, T. J. Jr, Breall, J. A., Moses, J. W., Eaton, G. M., Sklar, M. A., Lincoff, A. M. (2003). Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 41: 20-25 [Abstract] [Full Text]  
• Bailey, J. M., Tanaka, K. A., Levy, J. H. (2003). Cardiac Surgical Pharmacology. Card Surg Adult 2: 85-118 [Full Text]  
• Sheridan, P J, Crossman, D C (2002). Critical review of unstable angina and non-ST elevation myocardial infarction. Postgrad. Med. J. 78: 717-726 [Abstract] [Full Text]  
• Bates, S. M., Ginsberg, J. S. (2002). How we manage venous thromboembolism during pregnancy. Blood 100: 3470-3478 [Abstract] [Full Text]  
• Matsui, N. M., Varki, A., Embury, S. H. (2002). Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 100: 3790-3796 [Abstract] [Full Text]  
• Yang, S.-H., Lee, C.-H., Ko, S.-F., Chen, J.-B., Chung, F.-R., Hsu, K.-T. (2002). The successful treatment of renal-vein thrombosis by low-molecular-weight heparin in a steroid-sensitive nephrotic patient. Nephrol Dial Transplant 17: 2017-2019 [Full Text]  
• Whang, P. G., Lieberman, J. R. (2002). Low-Molecular-Weight Heparin. J Am Acad Orthop Surg 10: 299-302 [Full Text]  
• Walker, C. P. R., Royston, D. (2002). Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth 88: 848-863 [Abstract] [Full Text]  
• Hirsh, J., Lee, A. Y. Y. (2002). How we diagnose and treat deep vein thrombosis. Blood 99: 3102-3110 [Abstract] [Full Text]  
• Ageno, W., Turpie, A. G.G. (2002). New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins. CMAJ 166: 919-924 [Full Text]  
• Kim, M. C., Kini, A., Sharma, S. K. (2002). Refractory angina pectoris: Mechanism and therapeutic options. J Am Coll Cardiol 39: 923-934 [Abstract] [Full Text]  
• Weitz, J. I., Buller, H. R. (2002). Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future. Circulation 105: 1004-1011 [Full Text]  
• Antman, E.M., Cohen, M., McCabe, C., Goodman, S.G., Murphy, S.A., Braunwald, E. (2002). Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 23: 308-314 [Abstract] [Full Text]  
• Goldhaber, S.Z. (2002). Modern treatment of pulmonary embolism. Eur Respir J 19: 22S-27s [Abstract] [Full Text]  
• Dahm, M., Hafner, G., Schinzel, H., Mayer, E., Prufer, D., Oelert, H. (2001). Early antithrombotic management after valve replacement. Eur Heart J Suppl 3: Q12-Q15 [Abstract]  
• Hull, R. D., Pineo, G. F., Stein, P. D., Mah, A. F., MacIsaac, S. M., Dahl, O. E., Butcher, M., Brant, R. F., Ghali, W. A., Bergqvist, D., Raskob, G. E. (2001). Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review. ANN INTERN MED 135: 858-869 [Abstract] [Full Text]  
• Batchelor, W. B., Mahaffey, K. W., Berger, P. B., Deutsch, E., Meier, S., Hasselblad, V., Fry, E. T., Teirstein, P. S., Ross, A. M., Binanay, C. A., Zidar, J. P., the ATLAST Trial Investigators, (2001). A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J Am Coll Cardiol 38: 1608-1613 [Abstract] [Full Text]  
• Levy, J. H. (2001). Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann. Thorac. Surg. 72: S1814-1820 [Abstract] [Full Text]  
• Schweizer, J., Muller, A., Forkmann, L., Hellner, G., Kirch, W. (2001). Potential Use of a Low-Molecular-Weight Heparin to Prevent Restenosis in Patients with Extensive Wall Damage Following Peripheral Angioplasty. ANGIOLOGY 52: 659-669 [Abstract]  
• Ruiz-Irastorza, G, Khamashta, M A, Nelson-Piercy, C, Hughes, G R. (2001). Lupus pregnancy: is heparin a risk factor for osteoporosis?. Lupus 10: 597-600 [Abstract]  
• von Segesser, L. K, Mueller, X, Marty, B, Horisberger, J, Corno, A (2001). Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass. Perfusion 16: 411-416 [Abstract]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Arterioscler. Thromb. Vasc. Bio. 21 : e9-e9 [Full Text]  
• Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V. (2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Circulation 103: 2994-3018 [Full Text]  
• Pechlaner, C., Gritsch, W., Wiedermann, C. (2001). Enoxaparin for acute coronary syndromes?. J Am Coll Cardiol 37: 2007-2007 [Full Text]  
• Lopez-Sendon, J. (2001). Coronary reperfusion in the clinical setting: antithrombotic support to thrombolysis in the coronary care unit. Eur Heart J Suppl 3: C55-C61 [Abstract]